Johan Richter

Medicine & Life Sciences

1. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
2. Protein-Tyrosine Kinases 48%
3. Osteopetrosis 45%
4. Osteoclasts 34%
5. Imatinib Mesylate 34%
6. Diamond-Blackfan Anemia 27%
7. Dasatinib 25%
8. Hematopoietic Stem Cells 24%
9. Genetic Therapy 24%
10. ribosomal protein S19 20%
11. Myeloid Cells 17%
12. Genes 16%
13. Gaucher Disease 15%
14. Acute Myeloid Leukemia 14%
15. Therapeutics 13%
16. Stem Cells 13%
17. Leukemia, Myeloid, Chronic Phase 12%
18. Myeloid Progenitor Cells 11%
19. Bone and Bones 10%
20. Wilms' Tumor Genes 8%
21. Bone Marrow Cells 8%
22. Survival 8%
23. Antibodies 8%
24. retronectin 7%
25. Sweden 7%
26. Proton Pumps 7%
27. Bone Resorption 7%
28. Bone Marrow Failure Disorders 7%
29. Population 7%
30. Bone Marrow 7%
31. Wilms Tumor 7%
32. Natural Killer Cells 6%
33. Blood Cells 6%
34. Mouse Rps19 protein 6%
35. Glucosylceramidase 6%
36. Gibbon ape leukemia virus 6%
37. Mild autosomal recessive form Osteopetrosis 6%
38. Fetal Blood 6%
39. Registries 6%
40. Hematology 6%
41. 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 6%
42. Blast Crisis 6%
43. bosutinib 6%
44. Transplantation 6%
45. Osteogenesis 5%
46. Proteins 5%
47. Hematopoiesis 5%
48. eliglustat 5%
49. Busulfan 5%
50. Apoptosis 5%